Michael B. Dwinell, PhD

Professor; Founding Director, Center for Immunology; Director, Bobbie Nick Voss Laboratory for Colon Cancer Research; Leader, Molecular Cancer Therapeutics

Locations

Microbiology & Immunology
BSB 208

Contact Information

Biography

General Interests

Inflammation and Immunology, Cancer Biology

Education

PhD, GI Pathophysiology, University of Wisconsin, Madison, 1996

Research Interests

dwinell-lab

Dwinell Laboratory: Bobbie Nick Voss Laboratory for Colon Cancer Research

Research in the Dwinell laboratory seeks to define the role for extracellular mediators in the progression and metastasis of solid and hematological cancers. Additional studies are examining the role for metabolic reprogramming to influence tumor progression and exploring new mitochondria-targeted compounds as inhibitors of cancer progression. Human and murine 2D and 3D cell culture systems and preclinical models are being used to investigate the cellular, biochemical, and metabolic signaling pathways that regulate cellular proliferation, programmed cell death and motility in inflammation and cancer. Pharmacokinetic / pharmacodynamics, toxicity and potency / efficacy studies following treatment with small molecule or biologic compounds are also being completed. These translational research studies are multidisciplinary and include molecular cloning, cell culture, biochemical assays and signal processing, histopathology, flow cytometry, and small animal imaging and handling. Completion of these studies will strengthen our identification of new targets for therapeutic intervention to improve human health.to improve human health. There are currently two major research directions in the laboratory.

Research in the Dwinell laboratory is supported through grants from the National Institutes of Health, the Medical College of Wisconsin Cancer Center and philanthropic donations.

GEMMs Are a Gem When it Comes to Defining the Role of HIF2α in Mucinous Cystic Neoplasms.

(Boyle KA, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2018;5(2):165-166.
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

(Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335.
Corrigendum to 'A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds' [REDOX 14C (2017) 316-327].

(Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 06;16:426-427.
A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds.

(Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 04;14:316-327.
Differences in Sulfotyrosine Binding amongst CXCR1 and CXCR2 Chemokine Ligands.

(Moussouras NA, Getschman AE, Lackner ER, Veldkamp CT, Dwinell MB, Volkman BF.) Int J Mol Sci. 2017 Sep 03;18(9).
CCR7 Sulfotyrosine Enhances CCL21 Binding.

(Phillips AJ, Taleski D, Koplinski CA, Getschman AE, Moussouras NA, Richard AM, Peterson FC, Dwinell MB, Volkman BF, Payne RJ, Veldkamp CT.) Int J Mol Sci. 2017 Aug 25;18(9).
Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.

(Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell MB.) Cell Biochem Biophys. 2017 Dec;75(3-4):311-317.
Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms.

(Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell M.) Interface Focus. 2017 Apr 06;7(2):20160109.
Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.

(Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, St-Onge G, DiCosmo-Ponticello CJ, Koplinski CA, Roy I, Stephens B, Thelen S, Veldkamp CT, Coffman FD, Cohen MC, Dwinell MB, Thelen M, Peterson FC, Heveker N, Volkman BF.) Sci Signal. 2017 Mar 21;10(471).
Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma.

(Roy I, Boyle KA, Vonderhaar EP, Zimmerman NP, Gorse E, Mackinnon AC, Hwang RF, Franco-Barraza J, Cukierman E, Tsai S, Evans DB, Dwinell MB.) Lab Invest. 2017 03;97(3):302-317.
Exploiting agonist biased signaling of chemokines to target cancer.

(Roy I, Getschman AE, Volkman BF, Dwinell MB.) Mol Carcinog. 2017 03;56(3):804-813.
E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells.

(Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA.) Oncotarget. 2016 Jul 12;7(28):43363-43375.

Michael B. Dwinell, PhD